Epigenetic silencing of the MGMT gene by promoter methylation makes the tumor more sensitive to treatment with alkylating agents and has been associated with longer overall survival in patients with GBM who received TMZ chemotherapy (3). The gene discussed is MGMT; the disease is neoplasm.